New York, New York 11367

  • Depressive Symptoms

Purpose:

The purpose of the study is to examine the benefits and mechanism of action of computerized cognitive training (CCT) on mood, neuropsychological deficits, everyday functioning, and brain activity among young adults with a range of depressive symptoms.


Criteria:

Inclusion Criteria: 1. Age 18-29. 2. Current diagnosis of MDD/persistent depressive disorder or HDRS greater than or equal to 12. 3. Daily access to smartphone or tablet with internet connection for the study duration. 4. Willing and able to complete MRI, mood, and neuropsychological testing. 5. IQ > 85. Exclusion Criteria: 1. Lacks English-speaking ability as determined by self-report and clinical evaluation. 2. Evidence of schizophrenia, schizoaffective disorder, psychosis, bipolar I and II disorder. 3. Active suicidal ideation, intent, or plan, or past attempt within 1 year. 4. Severe depression (HDRS > 30). 5. Neurological disorder (epilepsy, multiple sclerosis, traumatic brain injury, clinical stroke). 6. Use of medications known to have negative impact on cognition (benzodiazepines and lorazepam equivalents > 1mg daily, narcotics, anticholinergics). 7. History of alcohol or drug abuse or dependence within past year. 8. Acute, severe, unstable medical illness. For cancer, acutely ill patients (including those with metastases) are excluded, but past history of successfully treated cancer does not result in exclusion. 9. Regular online brain training or regular player of non-fluency verbal games, defined as doing these procedures at a frequency of twice weekly or greater during the year prior to screening.


NCT ID:

NCT03869463


Primary Contact:

Principal Investigator
Joel R Sneed, PhD
Professor

Research Coordinator
Phone: 718-997-3226
Email: lifespandevelopmentlab@gmail.com


Backup Contact:

N/A


Location Contact:

New York, New York 11367
United States

Research Coordinator
Email: lifespandevelopmentlab@gmail.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.